These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II. Rubin AD; Wodchis WP; Spak C; Kileny PR; Hogikyan ND Arch Otolaryngol Head Neck Surg; 2004 Apr; 130(4):415-20. PubMed ID: 15096423 [TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia. Casserly P; Timon C J Laryngol Otol; 2008 Jan; 122(1):52-6. PubMed ID: 17470307 [TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital. Srirompotong S; Saeseow P; Taweesaengsuksakul R; Kharmwan S; Srirompotong S J Med Assoc Thai; 2006 Dec; 89(12):2077-80. PubMed ID: 17214059 [TBL] [Abstract][Full Text] [Related]
6. Perceptual analyses of spasmodic dysphonia before and after treatment. Cannito MP; Woodson GE; Murry T; Bender B Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1393-9. PubMed ID: 15611398 [TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type-A (Botox-A) injections for treatment of sialorrhoea in adults: a New Zealand study. Shetty S; Dawes P; Ruske D; Al-qudah M; Lyons B N Z Med J; 2006 Aug; 119(1240):U2129. PubMed ID: 16924280 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin A injection into corrugator muscle for frontally localised chronic daily headache or chronic tension-type headache. de Ru JA; Buwalda J J Laryngol Otol; 2009 Apr; 123(4):412-7. PubMed ID: 18588738 [TBL] [Abstract][Full Text] [Related]
9. Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia. Vasconcelos S; Birkent H; Sardesai MG; Merati AL; Hillel AD Laryngoscope; 2009 Oct; 119(10):2004-7. PubMed ID: 19572275 [TBL] [Abstract][Full Text] [Related]
10. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia. Stong BC; DelGaudio JM; Hapner ER; Johns MM Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357 [TBL] [Abstract][Full Text] [Related]
11. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414 [TBL] [Abstract][Full Text] [Related]
12. Voice related quality of life after botulinum toxin injection for spasmodic dysphonia. Gama AC; Menezes LN; Maia AA; Rezende Neto AL; Oliveira JB Rev Laryngol Otol Rhinol (Bord); 2010; 131(1):39-44. PubMed ID: 21077414 [TBL] [Abstract][Full Text] [Related]
13. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. de Bree R; Duyndam JE; Kuik DJ; Leemans CR Arch Otolaryngol Head Neck Surg; 2009 Mar; 135(3):287-90. PubMed ID: 19289708 [TBL] [Abstract][Full Text] [Related]
14. Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia. Klein AM; Stong BC; Wise J; DelGaudio JM; Hapner ER; Johns MM Otolaryngol Head Neck Surg; 2008 Sep; 139(3):421-3. PubMed ID: 18722224 [TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin A: a novel adjunct treatment for debilitating habit cough in children. Sipp JA; Haver KE; Masek BJ; Hartnick CJ Ear Nose Throat J; 2007 Sep; 86(9):570-2. PubMed ID: 17970150 [TBL] [Abstract][Full Text] [Related]
18. A survey of current practices of physicians who treat adductor spasmodic dysphonia in the U.S. Chang CY; Chabot P; Walz CM Ear Nose Throat J; 2009 May; 88(5):E18. PubMed ID: 19444777 [TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type A therapy during pregnancy. Newman WJ; Davis TL; Padaliya BB; Covington CD; Gill CE; Abramovitch AI; Charles PD Mov Disord; 2004 Nov; 19(11):1384-5. PubMed ID: 15389988 [TBL] [Abstract][Full Text] [Related]
20. Dermal and epidermal remodeling using botulinum toxin type A for facial, non reducible, hyperkinetic lines: two case studies. Bowler PJ J Cosmet Dermatol; 2008 Sep; 7(3):241-4. PubMed ID: 18789065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]